Proangiogenic effects of soluble α-Klotho (sKl) on systemic sclerosis (SSc) dermal microvascular endothelial cells (MVEC) Our findings provide the first evidence that α-Klotho is significantly decreased in the microvasculature in SSc skin and that sKl administration may effectively improve SSc–MVEC functions in vitro by acting as a powerful proangiogenic factor. BioMed Central, Arthritis Research & Therapy, 02/10/2017. (Also see Endothelin and Systemic Scleroderma)
Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis. Immunoreactivity to UL83 HCMV is frequent and strong in patients with SSc, implying a possible pathogenic role for this disease. PubMed, Clin Exp Rheumatol, 02/27/2017. (Also see Causes of Scleroderma: Infection)
Clinical utility of hypo– and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis (dcSSc). Our study demonstrates strong association of "salt and pepper" skin with dcSSc (69%), increased risk of pruritus and contractures. PubMed, Int J Rheum Dis, 03/06/2017. (Also see Hyperpigmentation and Hypopigmentation)
Characterization of the HLA-DRß1 third hypervariable region (3rd HVR) amino acid sequence according to charge and parental inheritance in systemic sclerosis (SSc). SSc patients differed from controls when DRB1 alleles were categorized according to 3rd HVR sequences. PubMed, Arthritis Res Ther, 2017 Mar 7;19(1):46. (Also see Hormones and Chromosomes in Scleroderma)
Corbus to Present Promising Data on Resunab as Systemic Sclerosis Treatment. Corbus Pharmaceuticals will present results showing that Resunab (JBT-101) can trigger specific molecular pathways which resolve inflammation and halt fibrosis. Scleroderma News, 03/07/2017. (Also see Clinical Trials)
Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. Our work suggests that IVIG are a safe therapeutic option that may be effective in improving musculoskeletal involvement, systemic inflammation, digestive tract symptoms and could be corticosteroid sparing. PubMed, Autoimmun Rev, 02/13/2017. (Also see IVIg)
Idiopathic and Systemic Sclerosis (SSc) associated Pulmonary Arterial Hypertension (PAH): A Comparison of Demographic, Haemodynamic and Magnetic Resonance Imaging Characteristics and Outcomes. The reasons for poorer outcomes in SSc–PAH are likely to be multifactorial including, but not limited to, older age and reduced gas transfer. PubMed, Chest, 02/18/2017. (Also see Pulmonary Hypertension Prognosis)
Treatment outcome in early diffuse cutaneous systemic sclerosis (dcSSc): the European Scleroderma Observational Study (ESOS). These findings may support using immunosuppressants for early dcSSc but suggest that overall benefit is modest over 12 months and that better treatments are needed. PubMed, Ann Rheum Dis, 02/10/2017. (Also see Immunosuppressants)
Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum (HICS) in systemic sclerosis. Our results suggest mechanisms of action for HICS, including upregulation of α-MSH, that has been shown to be anti–fibrotic in preclinical models, and possible markers to be included in future trials targeting skin in diffuse cutaneous systemic sclerosis. PubMed, Arthritis Res Ther, 2017 Mar 7;19(1):45. (Also see Clinical Trials)
Novel risk factors related to cancer in scleroderma (SSc). More studies are needed to ascertain the role of anti PM/Scl antibodies and aspirin in the development of malignancy among patients with SSc. PubMed, Autoimmun Rev, 03/08/2017. (Also see Cancer and Scleroderma)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: